Aligos Therapeutics (ALGS) Projected to Post Earnings on Tuesday

Aligos Therapeutics (NASDAQ:ALGS) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Aligos Therapeutics to post earnings of ($2.29) per share and revenue of $0.25 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 9:30 AM ET.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, beating the consensus estimate of ($2.09) by $0.18. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.27 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%. On average, analysts expect Aligos Therapeutics to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Aligos Therapeutics Stock Up 0.5%

Shares of Aligos Therapeutics stock opened at $6.43 on Tuesday. The firm has a market cap of $39.80 million, a price-to-earnings ratio of -0.75 and a beta of 2.62. The business has a fifty day simple moving average of $7.19 and a 200-day simple moving average of $8.32. Aligos Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $13.69.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Aligos Therapeutics in the 4th quarter worth about $215,000. SummitTX Capital L.P. acquired a new position in Aligos Therapeutics in the 4th quarter worth about $1,299,000. Verition Fund Management LLC acquired a new position in Aligos Therapeutics in the 4th quarter worth about $664,000. Marshall Wace LLP acquired a new position in Aligos Therapeutics in the 4th quarter worth about $2,504,000. Finally, Jane Street Group LLC acquired a new position in Aligos Therapeutics in the 4th quarter worth about $226,000. 60.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. Westpark Capital initiated coverage on Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 target price for the company. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. Finally, UBS Group initiated coverage on Aligos Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aligos Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $41.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.